Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The Effect of K ATP Channel Blocker Glibenclamide on CGRP-Induced Headache and Hemodynamic in Healthy Volunteers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Cerebral vs. Cardiovascular Responses to Exercise in Type 2 Diabetic Patients

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. Aerobic Exercise Training in Patients With mtDNA-Related Mitochondrial Myopathy

    Publikation: Bidrag til tidsskriftReviewpeer review

  1. The chronobiology of migraine: a systematic review

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. Timing and durability of response to erenumab in patients with chronic migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: Calcitonin gene-related peptide (CGRP) dilates cranial arteries and triggers headache. The CGRP signaling pathway is partly dependent on activation of ATP-sensitive potassium (K ATP ) channels. Here, we investigated the effect of the K ATP channel blocker glibenclamide on CGRP-induced headache and vascular changes in healthy volunteers.

Methods: In a randomized, double-blind, placebo-controlled, cross-over study, 20 healthy volunteers aged 18-27 years were randomly allocated to receive an intravenous infusion of 1.5 μg/min CGRP after oral pretreatment with glibenclamide (glibenclamide-CGRP day) or placebo (placebo-CGRP day). The primary endpoints were the difference in incidence of headache and the difference in area under the curve (AUC) for headache intensity scores (0-14 h) between glibenclamide and placebo. The secondary endpoints were the difference in AUC for middle cerebral artery blood flow velocity (V MCA ), superficial temporal artery (STA) and radial artery (RA) diameter, facial flushing, heart rate (HR) and mean arterial blood pressure (MAP) (0-4 h) between glibenclamide and placebo.

Results: We found no significant difference in the incidence of headache between glibenclamide-CGRP day (14/20, 70%) and placebo-CGRP day (19/20, 95%) (P = 0.06). The AUC for headache intensity, V MCA , STA, RA, facial skin blood flow, HR, and MAP did not differ between glibenclamide-CGRP day compared to placebo-CGRP day (P > 0.05).

Conclusion: Pretreatment with a non-selective K ATP channel inhibitor glibenclamide did not attenuate CGRP-induced headache and hemodynamic changes in healthy volunteers. We suggest that CGRP-induced responses could be mediated via activation of specific isoforms of sulfonylurea receptor subunits of K ATP channel.

OriginalsprogEngelsk
Artikelnummer652136
TidsskriftFrontiers in Physiology
Vol/bind12
Sider (fra-til)1-10
ISSN1664-042X
DOI
StatusUdgivet - 11 jun. 2021

ID: 66500595